Table 8.

Incidence of all-grade respiratory adverse events in cancer patients treated with ICI [66, 74–79, 101]

Drugs/irAE	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined treatment
Pneumonitis	0.4% [76] 1–5% [74] 1.4–2.0% [78] 2.7% [79] 3.8% [75]	0.4–2.2% [76] 0.7% [78] <1% [79] 7% [77]	2.1% [76] 3–7% [74] 6.5% [77] 7.5–10.5% [78] 9.6% [75] 10% [79]
Cough	4% [101]	NR	7.5% [101]
Dyspnea	3.3% [101] 4.5% [66]	4.2% [66]	9.4% [101] 10.2% [66]

NR not reported